Development and Evaluation of Gastro Retentive Floating Drug Delivery System of Ondansetron Hydrochloride

The Aim of the present study was to develop & evaluate Gastro-retentive floating Tablet of Ondansetron hydrochloride. The Objective was to calibrate and validate the UV- spectroscopy analytical method and to prepare and optimize the GR Floating tablets of Ondansetron hydrochloride in terms of dissolution release profile. The FDDS of the drug can minimize the fluctuation of drug plasma levels and result to associated adverse reactions, dosing frequency, and improved patient compliance. Conventionally, Ondansetron hydrochloride is taken up 2-3 times daily in the treatment of nausea and vomiting. Gastro retentive floating tablet of Ondansetron hydrochloride is better suited for treatment of postoperative nausea vomiting. In the present study, nine Gastro retentive Floating tablet formulations (F1, F2.....F9) of Ondansetron hydrochloride were prepared by the method of direct compression and polymers HPMC K15 were used and Guargum and Chitosan, in different quantity to normalise their effect on the’ release profile of drug . Target release profile was >80% release of drug in 12 hours. Tablets were evaluated for various parameters namely: thickness, weight variation’, friability, hardness, assay, in-vitro buoyancy study & drug release. Formulation F8 containing Chitosan (26.66% w/w), Guargum (26.66% w/w) and Sod. Carbonate (25.83% w/w) had the desirable release profile. Keywords: Ondansetron hydrochloride; Gastro retentive floating tablet, Chitosan, Guar gum, Drug release

NOVEL FLOATING AGENT SACCHAROMYCES BOULARDII FORMULATION BASED FLOATING DRUG DELIVERY SYSTEM

Objective: The objective is to design and optimize a floating tablet of furosemide using a novel floating agent Saccharomyces boulardii. Methods: In this study floating tablet based on principle of combination of floating and swelling prepared by direct compression technique. Saccharomyces boulardii probiotics preparation is used as a floating agent due to its bloating property i.e. production of CO2 gas and hydrophilic polymer HPMC E LV 15 used as swellable polymer. Furosemide is a BCS class IV drug selected as model drug which shows pH dependent solubility and permeability and it is better absorbed from the gastric region, hence to improve dissolution and residence at absorption site of such drug, floating drug delivery system is needed. Calcium hydroxide used as pH modifier which increase rate of dissolution of furosemide and also maintain integrity of tablet matrix. Formulation designed and developed using central composite design response surface methodology technique, so as to explore the effect of formulation variables such as amount of Saccharomyces boulardii preparation and calcium hydroxide on floating lag time and % drug release after 12h. Results: The numerical and graphical optimization technique were used to choose the optimal formulation. Floating lag time was found to be 12.6 min and 88.18% drug release for the optimized formulation. In vivo buoyancy studies depicted that formulation stay more then 6h in stomach. Conclusion: Study indicate that Saccharomyces boulardii is a promising floating agent, and the formulation containing this novel floating agent is suitable for gastro retention and it increases bioavailability of furosemide.

FORMULATION AND CHARACTERIZATION OF FLOATING TABLET DOSAGE FORM OF DUAL DELIVERY OF DRUG CURCUMIN AND BERBERINE HYDROCHLORIDE USING SIMULTANEOUS ESTIMATION BY UV SPECTROSCOPY

Objective: The present study was aimed to develop a combinational floating tablet of curcumin and berberine HCl utilizing synthetic polymers synthetic HPMC K-15M and evaluate its various characteristics. Methods: The formulations were developed by the process of wet granulation and evaluated for drug content, content uniformity, floating lag time, total floating time, in vitro buoyancy studies, and in vitro drug release profile. A simultaneous estimation method for curcumin and berberine was developed using U. V spectroscopy. Results: The results clearly indicated that the tablets produced were having acceptable physical parameters. The absence of any drug/polymer/excipient interactions was confirmed using infrared spectroscopy. It was found that the drug content of was in between 96.22 to 99.45 % in all the formulations. Because of their low densities, in vitro floatability tests showed that most of the tablets floated for more than 8 h. The in vitro release studies confirmed the sustained release of more than 80 percent of drug contained within a period of 8 h. In vitro buoyancy was good in all three batches (F1-F3). The overall floating time for the F2 formulation was 24 h. After one month of storage at 40 °C and 75 percent RH, the F2 formulation showed no noticeable change in physical as well as pharmaceutical performance characteristics. Conclusion: Floating tablets of curcumin and berberine was successfully developed and had passed on various pharmaceutical parameters.

Development of gastroretentiv floating tablets of losartan potassium by sublimation method

The purpose of present study was to formulate and Evaluate Sustained release floating tablet of losartan Potassium using Camphor and Polyethylene Oxide as Pore formation for floating and release retarding agent respectively to improve gastric residence time and patient compliance in management of hypertension. The tablet was prepared by direct compression by using HPMC K4 as dry binder. Camphor and PEO as floating and release retarding agent for sustained release floating tablet. Post compression was done to increase the hardness and floating time of tablet. Release modifier was used to speed up the release of drug from sustained release floating tablet. The effect of two independent variables like amount of Sublimating agent (camphor) and amount of Polyethylene oxide (PEO) on Q30min, Q360min, and Q720min was optimized using 32 factorial design and analyzed using the software design expert 10.0.3. The observed (actual values) responses were coincided well with the predicted values, given by the optimization technique. The floating tablet were characterized by FTIR for drug excipient compatibility.

Floating Drug Delivery System

Floating drug delivery system (FDDS) helps to improve the buoyancy property of the drug over the gastric fluids and hence maintain the longer duration of action. It is helpful in minimizing the dosing frequency. The density of dosage form must be less than the density of gastric contents (1.004 gm/ml) in FDDS. It may effervescent or non-effervescent system. The drugs having narrow absorption window in GIT is good candidate for the floating drug delivery system. The main objective of writing this review article is to compile the recent literature with special focus on classification, method of preparation, mechanism of action advantages and disadvantages. Keywords: Floating drug delivery system, Sustained release, controlled release, Floating tablet, Evaluation, Application, Gastro-retentive drug delivery system.

Development of Capsule containing Immediate Release Tablet and Extended Release Floating Tablet for Monitoring Release of Atenolol

Atenolol is beta blocker absorbed through GIT use for heart diseases. Single tablets, floating tablets and sustained released formulations studied are insufficient to produce effective dose to enhance bioavailability and effectiveness. Our study is focused on development of capsule dosage form containing immediate release (IR) and floating extended release (ER) tablets for monitoring release of atenolol in single dosage form. Two different tablets for IR and ER were prepared in three different combinations (Batch). Pre-formulation and post formulation parameters found to be within acceptable limits of formulation. Release behavior of individual tablets and capsule containing two tablets were studied. Among the batches, capsules containing smaller amount of atenolol in IR and large amount of Atenolol in ER (batch II) showed impressive drug release pattern. This formulation was stable even after a month and achieved optimum release behavior of immediate release and sustained release. This study could be used for effective treatment for different heart complications and reduce toxicity due to high plasma concentration in increased dose frequency.